A novel predictive score for hepatocellular carcinoma development in patients with chronic hepatitis C after sustained response to pegylated interferon and ribavirin combination therapy

Kuo Chin Chang, Chao Hung Hung, Sheng Nan Lu, Jing Houng Wang, Chuan Mo Lee, Chien Hung Chen, Ming Fang Yen, Sheng Chieh Lin, Yi Hao Yen, Ming Chao Tsai, Po Lin Tseng, Tsung Hui Hu

研究成果: 雜誌貢獻文章同行評審

62 引文 斯高帕斯(Scopus)

摘要

Objectives: Antiviral therapy can prevent the development of hepatocellular carcinoma (HCC) in chronic hepatitis C (CHC) patients. However, HCC still develops in patients achieving sustained virological response (SVR). We proposed to evaluate the risk factors and derive a novel risk score for HCC (score. HCC) by summation of products of clinical weights based on the regression coefficients in the final proportional hazards model. Methods: From March 2002 to October 2009, we enrolled 871 patients with biopsy-proven CHC, who received combined pegylated interferon and ribavirin therapy and achieved SVR. Results: Cox regression analysis showed that old age [hazard ratio (HR) 3.82, 95% CI 1.74-8.37, P = 0.001], high α-fetoprotein levels (HR 3.15, 95% CI 1.60-6.19, P = 0.001), low platelet counts (HR 2.81, 95% CI 1.22-6.44, P = 0.015) and high fibrotic stage (HR 3.95, 95% CI 1.46-10.70, P = 0.007) were independent risk factors. The cut-off level of risk scores was a derived value of 10 and was able to predict the HCC risk with 89.2% sensitivity and 69.5% specificity. The AUC value for the prediction was 0.848. The scoreHCC values were further categorized into three risk groups: low risk (scoreHCC ≤10), intermediate risk (scoreHCC 11-15) and high risk (scoreHCC ≥16). The proportion of HCC development increased from 1.37% (9/657) in the low-risk group to 9.14% (16/175) in the intermediate-risk group and 30.77% (12/39) in the high-risk group (P <0.001). Conclusions: With the novel risk scores, we can estimate the chance of HCC development more exactly and practically. This approach can be used for HCC screening in CHC patients achieving SVR.
原文英語
文章編號dks269
頁(從 - 到)2766-2772
頁數7
期刊Journal of Antimicrobial Chemotherapy
67
發行號11
DOIs
出版狀態已發佈 - 十一月 2012

ASJC Scopus subject areas

  • Pharmacology
  • Microbiology (medical)
  • Infectious Diseases
  • Pharmacology (medical)

指紋 深入研究「A novel predictive score for hepatocellular carcinoma development in patients with chronic hepatitis C after sustained response to pegylated interferon and ribavirin combination therapy」主題。共同形成了獨特的指紋。

引用此